Literature DB >> 11004738

Challenging the omnipotence of voices: group cognitive behavior therapy for voices.

P Chadwick1, S Sambrooke, S Rasch, E Davies.   

Abstract

The present study examines the impact of group based cognitive behavior therapy (CBT) for drug resistant auditory hallucinations, or voices. In particular it assesses treatment effect on beliefs in a voice's omnipotence and control. Twenty-two participants entered one of five 8-session CBT groups. Measures of omnipotence, control, process measures, and symptoms of anxiety and depression were completed at assessment, and first and last group sessions. The groups achieved a significant reduction in conviction in beliefs about omnipotence (df 2, P = 0.002) and control (df 2, P = 0.001). There were no affective changes. Certain participants showed important spontaneous changes in behavior. Process measures suggested that participants valued the groups and benefited from them. These results are promising and the treatment may prove a useful addition to existing psychological interventions.

Entities:  

Mesh:

Year:  2000        PMID: 11004738     DOI: 10.1016/s0005-7967(99)00126-6

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  11 in total

Review 1.  Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations.

Authors:  Max Birchwood; Zaffer Iqbal; Rachel Upthegrove
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 2.  The challenge of psychiatric rehabilitation in schizophrenia.

Authors:  S M Glynn
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

3.  Overgeneral autobiographical memory bias in clinical and non-clinical voice hearers.

Authors:  Pamela Jacobsen; Emmanuelle Peters; Thomas Ward; Philippa A Garety; Mike Jackson; Paul Chadwick
Journal:  Psychol Med       Date:  2018-03-14       Impact factor: 7.723

4.  A comprehensive review of auditory verbal hallucinations: lifetime prevalence, correlates and mechanisms in healthy and clinical individuals.

Authors:  Saskia de Leede-Smith; Emma Barkus
Journal:  Front Hum Neurosci       Date:  2013-07-16       Impact factor: 3.169

Review 5.  The Meaning of Voices in Understanding and Treating Psychosis: Moving Towards Intervention Informed by Collaborative Formulation.

Authors:  Aoife Lonergan
Journal:  Eur J Psychol       Date:  2017-05-31

6.  Change in the Neural Response to Auditory Deviance Following Cognitive Therapy for Hallucinations in Patients With Schizophrenia.

Authors:  Verner Knott; Nicola Wright; Dhrasti Shah; Ashley Baddeley; Hayley Bowers; Sara de la Salle; Alain Labelle
Journal:  Front Psychiatry       Date:  2020-06-12       Impact factor: 4.157

7.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis.

Authors:  Daniela Polese; Michele Fornaro; Mario Palermo; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

Review 8.  Psychological therapies for auditory hallucinations (voices): current status and key directions for future research.

Authors:  Neil Thomas; Mark Hayward; Emmanuelle Peters; Mark van der Gaag; Richard P Bentall; Jack Jenner; Clara Strauss; Iris E Sommer; Louise C Johns; Filippo Varese; José Manuel García-Montes; Flavie Waters; Guy Dodgson; Simon McCarthy-Jones
Journal:  Schizophr Bull       Date:  2014-07       Impact factor: 9.306

9.  Group mindfulness-based intervention for distressing voices: A pragmatic randomised controlled trial.

Authors:  Paul Chadwick; Clara Strauss; Anna-Marie Jones; David Kingdon; Lyn Ellett; Laura Dannahy; Mark Hayward
Journal:  Schizophr Res       Date:  2016-04-14       Impact factor: 4.939

Review 10.  Voluntary control of auditory hallucinations: phenomenology to therapeutic implications.

Authors:  Ariel Swyer; Albert R Powers
Journal:  NPJ Schizophr       Date:  2020-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.